Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 370 participants.

Also called NCT04778787

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 370 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04778787
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04778787. Randomized; single masking; primary purpose treatment. Start 2021-01-01 (actual); primary completion 2022-08-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention
Condition
Congestive Heart Failure
Intervention (Drug)
Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)
Lead sponsor
I.M. Sechenov First Moscow State Medical University (class: other)

Record details

Record id
cardio:ct-nct04778787
Content hash
1329ac14371aa2ae308c5596caa0b75a8615258d3418c2066a2b8b515468ebe5